2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Blood Banking, Clinical Procedures, Treatment Considerations, Combination Therapy, Drug Development, Drug-Drug Interactions, Supportive Care, Therapy Sequence, Biological Therapies, Transfusion, Vaccines, Non-Biological Therapies, Opioids, Women’s Health, Adverse Events, Biological Processes, Hematopoiesis, Metabolism, Clinical Practice (Health Services and Quality), Patient Safety, Quality Improvement, Quality of Care, Systems-Based Hematology, Diseases, Bleeding and Clotting, Thromboembolism, Thrombotic Disorders, Genetic Disorders, Hemoglobinopathies, Sickle Cell Disease, Sickle Cell Trait, Thalassemia, Immunology, Immunodeficiency, Infectious Diseases, Bacterial, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Pediatric, Young Adult
PAPER

4687 A clinical drug–drug interaction study evaluating the effect of etavopivat on sensitive substrates of CYP3A4 and key drug transporters supporting coadministration with common medications used in sickle cell disease and thalassemia

Sanjeev Forsyth, Ahad Sabet, MD, FACP, CPI2, Margrete Due Thomsen3
1 Novo Nordisk Inc, Plainsboro, New Jersey, United States
2 ICON, Salt Lake City, Utah, United States
3 Novo Nordisk, Aalborg, Denmark

Introduction: People with sickle cell disease (SCD) or thalassemia frequently require multiple concomitant medications for disease modification, supportive care, and treatment of comorbidities (Kato GJ et al. Nat Rev Dis Primers 2018;4:18010). As new oral disease-modifying therapies become available, a well-characterized drug–drug interaction (DDI) profile is important to support integration into routine clinical practice. Etavopivat is an orally bioavailable, small-molecule activator of the pyruvate kinase red blood cell isozyme currently in development for the treatment of SCD and thalassemia. This study (NCT06813924) investigated the clinical DDI profile of etavopivat by evaluating its effects on major cytochrome P (CYP) enzyme and transporter pathways, including CYP3A4, organic anion transporting polypeptide (OATP) 1B1/1B3, breast cancer resistance protein (BCRP), multidrug and toxin extrusion protein 1 (MATE-1), and P-glycoprotein (P-gp).

Methods: In this open-label, single-arm, fixed-sequence, two-period study, healthy adult participants received single doses of midazolam (2 mg; CYP3A4 substrate), pitavastatin (2 mg; OATP1B1/1B3 substrate), rosuvastatin (10 mg; BCRP and OATP1B1/1B3 substrate), metformin (500 mg; MATE-1 substrate), and digoxin (0.25 mg; P-gp substate) administered alone (Period 1) and following 400 mg once-daily etavopivat (Period 2). Serial pharmacokinetic, biomarker, and safety assessments were included throughout the study. Geometric mean ratios (GMRs; substrate with etavopivat/substrate without etavopivat) and 90% confidence intervals (CIs) were estimated for area under the curve (AUC) and maximum plasma concentration (Cmax). The pathways investigated in this clinical study were selected based on nonclinical DDI assessments, with study design and data interpretation based on the recommendations in ICH M12, with GMR (90% CI) within 80–125% proposed as a default no-effect boundary.

Results: Overall, 29 participants were included (14 female, 15 male). Mean age was 32.5 years, mean bodyweight 73.7 kg, and mean body mass index 25.1 kg/m2. There were 16 White participants, 7 Black or African American, and 5 were of other races. Etavopivat showed no clinically relevant inhibition or induction of CYP3A4, with midazolam exposure remaining within the no-effect boundaries following single (AUC) and multiple doses (AUC and Cmax) of etavopivat; Cmax following a single dose was slightly below the lower boundary. In addition, no clinically relevant effects were observed between etavopivat and rosuvastatin or metformin, indicating that etavopivat does not inhibit or induce BCRP or MATE-1, respectively. Minor increases in pitavastatin exposure were observed (GMRs: AUC 1.32, Cmax 1.36), suggesting a low likelihood of clinically relevant inhibition of OATP1B1/1B3. Digoxin AUC remained within the no-effect boundary, whereas a minor increase in Cmax was observed (GMR: 1.26 [90% CI, 1.12–1.43]), consistent with weak P-gp inhibition and supporting caution when etavopivat is coadministered with narrow therapeutic index P-gp substrates. Etavopivat was well tolerated. From first dose to study end, 37 treatment-emergent adverse events (TEAEs) occurred in 13/29 participants; all were mild in severity, and headache was the most common adverse event (AE), occurring in 6 participants. Investigators considered 23 TEAEs as possibly/probably related to study drugs including etavopivat; however, relatedness was non-specific as all these events were co-attributed to all study drugs, and no action was required with etavopivat. No participant required a dose reduction or drug discontinuation from etavopivat or substrate drugs, and there were no serious AEs or deaths.

Conclusions: The study findings indicated no clinically meaningful effects of etavopivat on CYP3A4 or the transporters evaluated, except for weak P-gp inhibition. Etavopivat was well tolerated, with AE frequency and symptom profile in line with expectations for a healthy-volunteer DDI study. Together, these findings support the use of etavopivat alongside the complex medication regimens that may be required by people living with SCD and thalassemia; specifically, medications whose disposition depends on CYP3A4 and drug transporter pathways, such as hormonal contraceptives, statins, selected opioids, and azole antifungals, while supporting appropriate caution when etavopivat is coadministered with narrow therapeutic index P-gp substrates.

Sanjeev Forsyth: Novo Nordisk A/S - Current equity holder in publicly-traded company; Novo Nordisk A/S - Current Employment